Spyre’s Insider Options Signal Confidence Ahead of IBD Milestones and Market Upside
Spyre Therapeutics’ new executive option grants signal confidence and long‑term commitment to its IBD antibody pipeline, highlighting potential upside and investor interest.
5 minutes to read